Abstract
"Virus-associated cancer" (VAC) refers to a cancer where viral infection results in the malignant transformation of the host's infected cells. Examples of viruses linked to cancers are the Epstein-Barr virus (EBV), which is associated with lymphomas, as well as nasopharyngeal and breast cancer; hepatitis B virus (HBV) and hepatitis C virus (HCV), which are both associated with hepatocellular carcinoma; and human papilloma viruses (HPVs), which are associated with cancer of the cervix. We have recently demonstrated that HIV-1-infected cells can be eliminated in vitro and in vivo by targeting viral glycoproteins expressed on the surface of infected cells with radiolabeled viral protein-specific monoclonal antibodies and proposed that this approach can be applicable to the broad range of viral infectious diseases. In VAC, the tumor cells can exhibit viral antigens both internally or on their surfaces. As a result, viral antigens in tumors represent a potential antigenic target that is clearly different from normal tissues. In principle, these proteins could be targeted by radioimmunotherapy (RIT). In this paper, we describe the potential of this approach and review some of the issues involved in the development of this approach. RIT of VAC is fundamentally different from the previously described uses of RIT, which have targeted tumor-associated antigens that are "self" proteins.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 303-308 |
| Number of pages | 6 |
| Journal | Cancer Biotherapy and Radiopharmaceuticals |
| Volume | 22 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 2007 |
Fingerprint
Keywords
- Radioimmunotherapy
- Viral infection
- Virus-associated cancer
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
- Oncology
Cite this
Targeting the virus with radioimmunotherapy in virus-associated cancers. / Dadachova, Ekaterina; Wang, Xing Guo; Casadevall, Arturo.
In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 22, No. 3, 06.2007, p. 303-308.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeting the virus with radioimmunotherapy in virus-associated cancers
AU - Dadachova, Ekaterina
AU - Wang, Xing Guo
AU - Casadevall, Arturo
PY - 2007/6
Y1 - 2007/6
N2 - "Virus-associated cancer" (VAC) refers to a cancer where viral infection results in the malignant transformation of the host's infected cells. Examples of viruses linked to cancers are the Epstein-Barr virus (EBV), which is associated with lymphomas, as well as nasopharyngeal and breast cancer; hepatitis B virus (HBV) and hepatitis C virus (HCV), which are both associated with hepatocellular carcinoma; and human papilloma viruses (HPVs), which are associated with cancer of the cervix. We have recently demonstrated that HIV-1-infected cells can be eliminated in vitro and in vivo by targeting viral glycoproteins expressed on the surface of infected cells with radiolabeled viral protein-specific monoclonal antibodies and proposed that this approach can be applicable to the broad range of viral infectious diseases. In VAC, the tumor cells can exhibit viral antigens both internally or on their surfaces. As a result, viral antigens in tumors represent a potential antigenic target that is clearly different from normal tissues. In principle, these proteins could be targeted by radioimmunotherapy (RIT). In this paper, we describe the potential of this approach and review some of the issues involved in the development of this approach. RIT of VAC is fundamentally different from the previously described uses of RIT, which have targeted tumor-associated antigens that are "self" proteins.
AB - "Virus-associated cancer" (VAC) refers to a cancer where viral infection results in the malignant transformation of the host's infected cells. Examples of viruses linked to cancers are the Epstein-Barr virus (EBV), which is associated with lymphomas, as well as nasopharyngeal and breast cancer; hepatitis B virus (HBV) and hepatitis C virus (HCV), which are both associated with hepatocellular carcinoma; and human papilloma viruses (HPVs), which are associated with cancer of the cervix. We have recently demonstrated that HIV-1-infected cells can be eliminated in vitro and in vivo by targeting viral glycoproteins expressed on the surface of infected cells with radiolabeled viral protein-specific monoclonal antibodies and proposed that this approach can be applicable to the broad range of viral infectious diseases. In VAC, the tumor cells can exhibit viral antigens both internally or on their surfaces. As a result, viral antigens in tumors represent a potential antigenic target that is clearly different from normal tissues. In principle, these proteins could be targeted by radioimmunotherapy (RIT). In this paper, we describe the potential of this approach and review some of the issues involved in the development of this approach. RIT of VAC is fundamentally different from the previously described uses of RIT, which have targeted tumor-associated antigens that are "self" proteins.
KW - Radioimmunotherapy
KW - Viral infection
KW - Virus-associated cancer
UR - http://www.scopus.com/inward/record.url?scp=34447503809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34447503809&partnerID=8YFLogxK
U2 - 10.1089/cbr.2007.344
DO - 10.1089/cbr.2007.344
M3 - Article
C2 - 17651036
AN - SCOPUS:34447503809
VL - 22
SP - 303
EP - 308
JO - Cancer Biotherapy and Radiopharmaceuticals
JF - Cancer Biotherapy and Radiopharmaceuticals
SN - 1084-9785
IS - 3
ER -